Supplemental Tables

Supplemental Table 1. Imaging parameters of preoperative brain MR imaging

Achieva / SKYRA / Avanto
TOF / CE-MRA / T2 / FLAIR / TOF / CE-MRA / T2 / FLAIR / TOF / CE-MRA / T2 / FLAIR
TR/TE / 25/3.5 / 6.9/1.9 / 3000/80 / 11000/125 / 21/3.69 / 3.54/1.39 / 3980/129 / 10000/123 / 24 / 7 / 3.67/1.31 / 4030/103 / 9000/109
Field of view / 250 x 200 / 320 x 320 / 210 x 210 / 210 x 210 / 220 x 198 / 320 x 250 / 210 x 210 / 210 x 210 / 230 x 198 / 320 x 250 / 182 x 210 / 183 x 210
Matrix / 756 x 334 / 756 x 334 / 512 x 512 / 512 x 512 / 448 x 320 / 576 x 408 / 512 x 512 / 384 x 384 / 320 x 320 / 320 x 320 / 448 x 390 / 256 x 224
Flip angle / 20 / 20 / 90 / 90 / 22 / 22 / 150 / 150 / 23 / 30 / 150 / 150
Thickness /gap(mm) / 0.6/0 / 0.5/0 / 5.0/2.0 / 5.0/2.0 / 0.5/0 / 0.5/0 / 5.0/2.0 / 5.0/2.0 / 0.6/0 / 0.5/0 / 5.0/2.0 / 5.0/2.0
Number of Excitation / 1.0 / 1.0 / 2.0 / 2.0 / 2.0 / 1.0
Scan time / 7 min 26 sec / 1 min 26 sec / 1 min 48 sec / 2 min 12 sec / 7 min 59 sec / 49 sec / 2 min 11 sec / 3 min 18 sec / 7min 44 sec / 1 min 44 sec / 1 min 42 sec / 2 min 08 sec

Note-CE indicates contrast enhance; MRA, magnetic resonance angiography; TE, echo time; TOF, time-of-flight; TR, repetition time.

1

Supplemental Table 2. Baseline liver cirrhosis-related parameters in patients with liver cirrhosis

Patients (n = 1460)
Etiology of liver cirrhosis
HBV / 1041 (71.3)
HCV / 108 (7.4)
HBV + HCV / 7 (0.5)
Alcohol + HBV / 49 (3.4)
Alcohol + HCV / 3 (0.2)
Alcohol / 196 (13.4)
Others / 104 (7.1)
INR / 1.6 ± 0.7
Bilirubin, mg/dL / 5.7 ± 9.2
Albumin, g/dL / 3.2 ± 0.6
Creatinine, mg/dL / 1.0 ± 0.9
Platelet count, 103/μL / 65.6 ± 36.1
CTP classification
A/B/C / 424(29.0)/572(39.2)/464(31.8)
MELD score / 16.1 ± 8.2
Presence of HCC / 792 (54.2)

Data are presented as n (%), or mean ± standard deviation.

Note-CTP, Child-Turcotte-Pugh; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease.

1

Supplemental Table 3. Risk factors for significant white matter lesions in the pooled cohort

Significant white matter lesionsa (210/6365 patientsb)
Univariate / Multivariable
OR / 95% CI / P / OR / 95% CI / P
Liver cirrhosis / 0.69 / 0.45–1.05 / 0.085 / 1.84 / 1.16–2.91 / 0.009
Male / 0.54 / 0.41–0.71 / 0.001
Age / < 50 / 1.00 / 0.001 / 1.00 / 0.001
50–59 / 3.31 / 1.31–8.39 / 0.011 / 3.20 / 1.26–8.14 / 0.015
60–69 / 13.56 / 5.48–33.57 / 0.001 / 11.51 / 4.59–28.86 / 0.001
≥70 / 61.61 / 24.77–153.24 / 0.001 / 49.39 / 19.38–125.88 / 0.001
Body mass index / 1.03 / 0.99–1.08 / 0.189
Diabetes mellitus / 1.52 / 1.12–2.07 / 0.008
Hypertension / 4.00 / 2.99–5.27 / 0.001 / 2.69 / 1.97–3.67 / 0.001
Hyperlipidemia / 1.55 / 1.12–2.15 / 0.008
Stroke history / 2.86 / 1.66–4.95 / 0.001 / 1.88 / 1.04–3.38 / 0.036
Family history of stoke / 1.17 / 0.87–1.56 / 0.300
Smoking / Current / 0.48 / 0.31–0.75 / 0.001 / 0.80 / 0.50–1.28 / 0.344
Former / 0.48 / 0.34–0.66 / 0.001 / 0.47 / 0.33–0.66 / 0.001
Never / 1.00 / 0.001 / 1.00 / 0.001
Alcohol / 0.95 / 0.51–1.77 / 0.882

Note- CI indicates confidence interval; OR,odds ratio.

aSignificant white matter lesions were defined as more than moderate degree of Fazekas scale.

b1034 of 1460 cirrhotic patients who underwent both MRA and MRI were included in the analysis of white matter lesion.

Supplemental Table 4. Risk factors for significant white matter lesions in the patients with liver cirrhosis

Significant white matter lesionsa (25/1034patientsb)
Univariate / Multivariable
OR / 95% CI / P / OR / 95% CI / P
Stroke risk factors
Male / 0.6 / 0.26–1.41 / 0.24
Age / 1.15 / 1.08–1.22 / 0.001 / 1.13 / 1.06–1.21 / 0.001
Body mass index / 1.01 / 0.90–1.13 / 0.917
Diabetes Mellitus / 1.21 / 0.50–2.92 / 0.678
Hypertension / 3.74 / 1.67–8.38 / 0.001 / 2.75 / 1.19–6.36 / 0.018
Hyperlipidemia / 1
Stroke history / 4.16 / 0.51–33.82 / 0.182
Family history of stoke / 1.35 / 0.31–5.87 / 0.688
Smoking / Current / 1 / 0.33–3.04 / 0.998 / 1.59 / 0.50–5.07 / 0.432
Former / 0.24 / 0.08–0.70 / 0.01 / 0.26 / 0.08–0.78 / 0.016
Never / 1 / 0.01 / 1
Alcohol / 1.06 / 0.36–3.12 / 0.919
Cirrhosis-related factors
Hepatocellular carcinoma / 1.18 / 0.53–2.66 / 0.683
Etiology of liver cirrhosis
HBV / 0.44 / 0.20-0.99 / 0.047
HCV / 1.75 / 0.51–5.98 / 0.373
Alcoholic / 1.07 / 0.36–3.17 / 0.897
Other / 2.86 / 0.95–8.59 / 0.061
Hepatic encephalopathy / Severe / 2.13 / 0.71–6.41 / 0.178
Mild / 1.41 / 0.32–6.21 / 0.646
No / 1 / 0.437
MELD Score / 1.02 / 0.98-1.07 / 0.284

Note- CI indicates confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, Model for End-Stage Liver Disease; OR, odds ratio.

aSignificant white matter lesions were defined as more than moderate degree of Fazekas scale.

b1034 of 1460 cirrhotic patients who underwent both MRA and MRI were included in the analysis of white matter lesions.

Supplementa1Materials

Pretransplantation Workup

All LT candidates at our institution underwent pretransplant neurology workup, including a detailed clinical history, physical examination, and neurologic examination. MRA with or without MRI was conducted on possible LT candidates > 35 years of age. In the case of HCC, we included contrast-enhanced T1-weighted image in order to rule out intracranial metastasis.

1